NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
17 trialsNCT03737994 2026-04-07
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02664935 2025-05-21
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Active not recruiting
NCT06563999 2024-12-10
NUMER
Sun Yat-sen University
Phase 2 Recruiting
NCT04322890 2024-10-22
PIKACHU
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05014464 2024-09-20
ATPase
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT04084717 2024-07-16
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
University Health Network, Toronto
Phase 2 Recruiting
NCT04322578 2024-06-04
CONFIRM
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT03574402 2022-12-06
TRUMP
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT02183870 2022-06-16
EUCROSS
University of Cologne
Phase 2 Completed
NCT03088930 2022-02-11
Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
University of Colorado, Denver
Phase 2 Completed
NCT01945021 2021-02-21
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
Pfizer
Phase 2 Completed
NCT02134912 2020-02-20
S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
SWOG Cancer Research Network
Phase 2 Terminated
NCT01822496 2019-08-05
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02499614 2017-10-25
METROS
Fondazione Ricerca Traslazionale
Phase 2 Unknown
NCT00932451 2017-01-13
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Pfizer
Phase 2 Completed
NCT01500824 2013-02-25
A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 2 Withdrawn